Hologic — Debt Investor Presentation (July 2013)
30 slides from Hologic's debt investor presentation, Jul 23, 2013
Slide 1: Presentation to Lenders
Exhibit 99.1 Presentation to Lenders July 23, 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herei
Slide 3: Third Quarter Fiscal 2013 Preliminary Financial Information
Third Quarter Fiscal 2013 Preliminary Financial Information The preliminary financial information presented in this presentation represents estimates only, as the Company has not completed its financial statements for its third quarter ended June 29, 2013 and its independent auditor has not complete
Slide 4: Transaction Overview
Transaction Overview Hologic, Inc. ("Hologic" or "the Company") (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women Hologic has continued to demonstr
Slide 5: Pro Forma Capitalization
Pro Forma Capitalization Amounts as of March 30, 2013 ($ in millions) Current Pro Forma Amount Amount Leverage Maturity Put Date Cash $ 745 $ 545 Revolver ($300mm) - - 0.0 x Aug-17 Term Loan A 969 969 1.0 x Aug-17 Extant Term Loan B 1,479 - 1.0 x Aug-19 New Term Loan B - 1,279 2.3 x Aug-19 Total Sec
Slide 6: Total Revenues by Business Segment
Total Revenues by Business Segment Consolidated Non-GAAP Q2’13 Revenues of $619.1M (unaudited)* Total Diagnostics $302.9M* 49% 19% Capital Equipment Breast Health $220.1M 35% 15% 66% Consumables Service GYN Surgical $73.7M 12% Skeletal Health $22.4M 4% Consumables/Service ~81% Capital Equipment ~19%
Slide 7: Two Exciting New Product Cycles are Just Beginning
Two Exciting New Product Cycles are Just Beginning • Early stage of a promising replacement cycle with technology superior to 2D digital • Recent peer-reviewed publications further support adoption Dimensions 3D Breast Tomosynthesis • Ability to offer class-leading automation to low- and medium-volu
Slide 8: Diagnostics – Leadership in Cytology and Molecular Diagnostics
Diagnostics – Leadership in Cytology and Molecular Diagnostics • Premier automated solutions • Proprietary chemistries: TMA (Transcription-mediated amplification) and Invader • Extending leadership from cytology into molecular via Gen-Probe acquisition • Validated by #1 or #2 U.S. market share in ke
Slide 9: Comprehensive Cervical Cancer Screening Solution
Comprehensive Cervical Cancer Screening Solution • The only FDA approved complete cervical cancer screening solution to include liquid-based cytology + HPV (high-risk and genotyping) • All from our ThinPrep vial, the gold standard in cervical cytology • Thoughtfully designed HPV products designed to
Slide 10: Flagship Brand in STD Testing
Flagship Brand in STD Testing • APTIMA Combo 2 assay remains a growth driver • < 40% of sexually active women aged 25 and under in the U.S. are screened for chlamydia and gonorrhea • Improved compliance and international expansion opportunities • APTIMA Trichomonas experiencing rapid adoption • Tric
Slide 11: Broad Portfolio of MDx Instrumentation
Broad Portfolio of MDx Instrumentation V o l u m e Reference Labs Hospital Labs Uniquely Positioned in Molecular Diagnostics • Already leading in high-volume setting • Ability to capitalize on lab decentralization trend with introduction of PANTHER • Proprietary chemistries, TMA and INVADER, offer f
Slide 12: Integrated Sales Organization with a Clear Strategy
Integrated Sales Organization with a Clear Strategy Combined Sales Call Point Molecular Lab Cytology Lab Physician Drive Test Utilization Drive Compliance Communicate Guidelines Portfolio of Products Combined Company Menu HPV CT/NG Trichomonas ThinPrep fFn - APTIMA & Imaging - Cervista - Genotyping
Slide 13: Our Lab Partners
Our Lab Partners The value of a Hologic partnership to our Lab Partners: • Grow revenue • Increase operational effectiveness • Provide patients and clinicians with leading women's health diagnostic solutions 13
Slide 14: Breast Health – Mammography
Breast Health – Mammography Leader in Breast Cancer Screening & Diagnosis • Market leadership: ~65% of current U.S. installed base, ~40% OUS • Approximate $4 billion addressable U.S. market • Strong competitive advantages of 3D Dimensions Clinical superiority to 2D First-to-market with no U.S. compe
Slide 15: Advancing Breast Cancer Screening
Advancing Breast Cancer Screening 15
Slide 16: 3D Dimensions Tomosynthesis
3D Dimensions Tomosynthesis Superior Next-Generation Digital Mammography Improved Tissue Visualization and Detection Superiority over 2D Digital Mammography Lower Recall Rates Tomosynthesis…uptake ahead of expectations • U.S. installed base of ~11,000 digital systems – potential for conversion to To
Slide 17: Tomosynthesis Clinical Efficacy
Tomosynthesis Clinical Efficacy Oslo Tomosynthesis Screening Trial Compared to 2D, U.S. sites report a reported breast cancer screening significant reduction in recalls with with Hologic Tomosynthesis significantly Hologic Tomosynthesis 2-3 1 improves cancer detection 40% 27% in invasive overall in
Slide 18: Tomosynthesis + C-View 2D: A superior mammography exam
Tomosynthesis + C-View 2D: A superior mammography exam 1 • Less patient dose through reduced x-ray exposures • Greater patient comfort via fast, 4 second scan time • Heightened detail from tomosynthesis images • Superior performance compared to traditional 2D alone 1. Compared to 2D alone. FDA PMA s
Slide 19: MyoSure a Growth Driver in GYN Surgical
MyoSure a Growth Driver in GYN Surgical MyoSure Hysteroscopic Tissue Removal System • Minimally-invasive technology to remove fibroids and polyps • Dynamic technology in early stages of adoption • Potential $300-400 million annual opportunity in the U.S. • Product line extensions offer flexibility t
Slide 20: Q2 FY 2013 Overview
Q2 FY 2013 Overview Quarter Ended March 30, 2013 (unaudited) Key Performance Metrics Q2 FY 2013 GAAP revenues of $612.7 million and non-GAAP Revenues* revenues of $619.1 million 1 • Non-GAAP revenues up $147.9 million, or 31.4%, vs. Q2’12 • Non-GAAP revenues down $25.5 million, or 4.0%, vs. Q1’13 GA
Slide 21: Q2 FY 2013 Summary
Q2 FY 2013 Summary Financing Activities • Sale of LIFECODES business unit for approximately $85 million in cash, adjusted for working capital items, with the opportunity to earn a contingent payment of $10 million • Successful transaction retiring $370 million, 2.00% Convertible Senior Notes due 203
Slide 22: Business Segments
Business Segments Breakdown of consolidated Non-GAAP Q2’13 Revenues of $619.1M (unaudited)* 49% 66% Diagnostics Consumables 12% GYN Surgical 15% 35% Service 19% Breast Health Capital Equipment U.S. Revenues ~ 75% Disposables/Service ~ 81% International Revenues ~ 25% Capital Equipment ~ 19% * Q2’13
Slide 23: Q2 FY 2013 Diagnostics Summary
Q2 FY 2013 Diagnostics Summary Diagnostics • Continued #1 U.S. market share for ThinPrep • Continued #1 U.S. market share for APTIMA Combo 2 for CT/GC • Continued #1 U.S. market share for PROCLEIX in blood screening • Continued competitive wins for ThinPrep, HPV and CT/GC • PANTHER launch progressin
Slide 24: Q2 FY 2013 Breast Health Summary
Q2 FY 2013 Breast Health Summary Breast Health • Continued #1 U.S. market share for digital mammography placements in the U.S. • Successfully met two-year unit tomosynthesis goal by end of Q2’13 and the goal is to more than double year-over-year placements in Fiscal 2013 • Record biopsy sales both i
Slide 25: Q2 FY 2013 GYN Surgical Summary
Q2 FY 2013 GYN Surgical Summary GYN Surgical • #1 share for MyoSure in the U.S. hysteroscopic morcellation market • Continued #1 market share for NovaSure in the GEA (Global Endometrial Ablation) market • Strong quarter for MyoSure with double-digit sequential and year-over-year growth • Growing dem
Slide 26: Amendment Overview
Amendment Overview Hologic is seeking to reprice its Term Loan B The amendment would also expand the Company’s general basket for Restricted Junior Payments to $250mm and increase the total net leverage threshold for accessing the excess cash flow builder component from 3.5x to 4.0x In addition, the
Slide 27: Slide 27
Slide 28: Reconciliation of GAAP to Non-GAAP
Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except earnings per share Three Months Ended March 30, 2013 March 24, 2012 December 29, 2012 REVENUES GAAP revenues $612,663 - $631,362 Net adjustments primarily related to Novartis 6,429 - 13,275 collaboration Non-GAAP revenues $619,092 $
Slide 29: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except earnings per share Three Months Ended March 30, 2013 March 24, 2012 December 29, 2012 OPERATING EXPENSES GAAP operating expenses $273,784 $215,976 $218,444 Adjustments: Amortization of intangible assets (28,667) (16,629) (28,526) Co
Slide 30: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Hologic has presented the following non-GAAP financial measures in this presentation: revenues; gross margins; operating expenses; operating income; interest expense; pre-tax income; net income; EPS; and EBITDA. Hologic defines its non-GAAP revenues to primarily in